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Despite high response rates and significantly prolonged survival,
chemotherapy is associated with only a small percentage of cures
in small-cell lung cancer (SCLC) (Paesmans et al, 2000). 5-year
overall survival rate rarely exceeds 10% and there are 10 times
more long-term survivors in patients with limited disease (LD)
than in these with extensive disease. Various attempts have been
performed to improve these results, some successful as combina-
tion with chest irradiation (Pignon et al, 1992; Warde and Payne,
1992; Luce et al, 1998) but others without significant benefit such
as the administration of alternating or sequential combination
chemotherapy (Johnson, 1999). 
Intensive chemotherapy is an attractive approach to improve
survival in SCLC (Sculier and Klastersky, 1989). It can be
performed by various types of escalation: increasing the number of
active drugs in the combination or the dosage of the administered
agents, enhancing the duration of treatment by consolidation and/or
maintenance regimens, providing weekly chemotherapy treatments
or reducing the intervals between courses of chemotherapy. The
European Lung Cancer Working Party (ELCWP) has already
assessed some of these concepts in various randomised trials
(Sculier et al, 1990, 1993, 1996) and has designed in the early 1990s
a trial evaluating accelerated chemotherapy. 
Accelerated chemotherapy is an intensive treatment obtained by
reducing the intervals between the courses, leading to increased
dose-intensity. It has been shown that this approach can be opti-
mised by using haematopoietic growth factors, mainly GM-CSF
and G-CSF (Thatcher, 1992). G-CSF (granulocyte-colony stimu-
lating factor) preferentially stimulates neutrophil production and
has been shown to reduce the duration of neutropenia following
chemotherapy (Lieschke and Burgess, 1992a, b). GM-CSF (granu-
locyte-macrophage colony stimulating factor) stimulates neutrophil,
monocyte and eosinophil production and function. It is associated
with more diverse haematological and clinical effects, including
improvement of host defence mechanisms. 
Both growth factors have been shown able to reduce, in SCLC,
the duration of neutropenia induced by chemotherapy and to
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Summary The European Lung Cancer Working Party (ELCWP) designed a 3-arm phase III randomised trial to determine the role of
accelerated chemotherapy in extensive-disease (ED) small-cell lung cancer (SCLC). Eligible patients were randomised between the 3
following arms: (A) Standard chemotherapy with 6 courses of EVI (epirubicin 60 mg m–2, vindesine 3 mg m–2, ifosfamide 5 g m–2; all drugs
given on day 1 repeated every three weeks. (B) Accelerated chemotherapy with EVI administered every 2 weeks and GM-CSF support. (C)
Accelerated chemotherapy with EVI and oral antibiotics (cotrimoxazole). Primary endpoint was survival. 233 eligible patients were
randomised. Chemotherapy could be significantly accelerated in arm B with increased absolute dose-intensity. Best response rates, in the
population of evaluable patients, were, respectively for arm A, B and C, 59%, 76% and 70%. The response rate was significantly higher in arm
B in comparison to arm A (P = 0.04). There was, however, no survival difference with respective median duration and 2-year rate of 286 days
and 5% for arm A, 264 days and 6% for arm B and 264 days and 6% for arm C. Severe thrombopenia occurred more frequently in arm B but
without an increased rate of bleeding. Non-severe infections were more frequent in arm B and severe infections were less frequent in arm C.
Our trial failed to demonstrate, in ED-SCLC, a survival benefit of chemotherapy acceleration by using GM-CSF support. © 2001 Cancer
Research Campaign http://www.bjcancer.com 
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reduce the number of febrile neutropenia episodes (Crawford et al,
1991; Trillet-Lenoir et al, 1993, 1995; Hamm et al, 1994). This
latter benefit can however be obtained with oral antibiotics
prophylaxis such as contrimoxazole as shown in 2 randomised
trials (de Jongh et al, 1983; Figueredo et al, 1985). 
All these considerations have led the ELCWP to perform in ED
SCLC a 3-arm randomised trial, having survival as primary
endpoint and comparing to standard 3-weekly chemotherapy, 
2-weekly accelerated treatment using the same chemotherapy
regimen supported by haematopoietic growth factor (GM-CSF) or
by oral prophylactic antibiotics (cotrimoxazole). 
PATIENTS AND METHODS 
To be eligible for study entry, patients with pathologically proven
SCLC (using World Health Organisation (WHO) classification)
had to present with extensive disease. Extensive disease was
defined as a disease with distant metastases or as a locoregional
disease that could not be locally treated in a single radiotherapy
field. The patients should not have received any prior therapy
(radiotherapy, chemotherapy or surgery), had to have a Karnofsky
performance status (PS) of at least 60, an evaluable or measurable
lesion, and no history of prior malignant tumour except non-
melanoma skin cancer or in situ carcinoma of the cervix. In addi-
tion, they had to have adequate haematologic (WBC count ≥ 4000
mm–3 and platelet count ≥ 100 000 mm–3), renal (serum creatinine
< 1.5 mg dl–1) and hepatic (serum bilirubin < 1.5 mg dl–1) functions,
age less than 75 years, no recent myocardial infection (< 3 months
before date of diagnosis), no congestive cardiac failure and cardiac
arrhythmia requiring medical treatment, no uncontrolled infectious
disease, no history of allergy to cotrimoxazole sulfamides, and no
other serious medical or psychologic factors which might prevent
adherence to the treatment schedule; patients had to be accessible
for follow-up and to provide informed consent. Study protocol was
approved by the ethical committee of the hospitals. 
Eligible patients were randomised to receive 6 courses of EVI
(epirubicin 90 mg m–2, vindesine 3 mg m–2 and ifosfamide 5 g m–2;
all drugs given i.v. on day 1) according to 3 different schedules:
(A) Standard arm (administration every 3 weeks); (B) Accelerated
arm (administration every 2 weeks) with GM-CSF support; (C)
Accelerated arm (administration every 2 weeks) with oral antibi-
otics support (cotrimoxazole). In the 2 accelerated arms, treatment
was delayed by one week if on day 15, the neutrophil count was <
1000 mm–3 and/or the platelet count < 75 000 mm–3. Vindesine and
epirubicin were administered by i.v. bolus. Ifosfamide was admin-
istered as 24-h i.v. infusion in 1 l NaCl 0.9%. Mesna was infused at
a dose ratio 1 g mesna 1 g–1 ifosfamide in 11 dextrose 5% NaCl
0.45% over 24 hours, starting at the onset of ifosfamide infusion
and followed by an infusion at the ratio 500 mg mesna 1 g–1 ifos-
famide in 1 1 dextrose 5% NaCl 0.45% over 2 hours. GM-CSF
(Leucomax, kindly provided by the Schering-Plough company)
was given, as a daily subcutaneous dose of 5 µ g kg–1, from day 3
through day 13 or until neutrophil count reached ≥ 4000 mm–3
after nadir. If neutrophils were < 1000 mm–3 on day 13, adminis-
tration of GM-CSF was continued until reaching this level.
Cotrimoxazole (160 mg trimethoprim plus 800 mg sulfamethoxa-
zole) was administered orally every 12 hours from day 3 until the
end of the courses of chemotherapy. 
Tumour response was assessed after the first 3 courses of
chemotherapy and again after completion of therapy. Patients with
no change or disease progression after 3 courses were withdrawn
from treatment. The total number of courses of chemotherapy was
limited to 6 for the responders. In case of recurrence, if the treat-
ment-free interval was greater than 6 months, new courses of EVI
were administered. Otherwise, patients went off trial. 
The dose-adaptation plan for drugs was as follows: in the stan-
dard arm, EVI dosage was reduced by 25% in case of neutrophil
nadir < 500 mm–3 and/or platelet nadir < 25 000 mm–3 and treat-
ment had to be delayed by one week in absence of full haematolog-
ical recovery (i.e. neutrophil count > 1500 mm–3 and platelet count
> 100 000 mm–3). In the accelerated arms, treatment was delayed
by one week if on day 15, neutrophil count was < 1000 mm–3
and/or platelet count < 75 000 mm–3. In any arm, if the delay
between 2 courses of chemotherapy was more than 5 weeks, the
patient was taken off treatment. Epirubicin was discontined in cases
of cardiac toxicity. WHO criteria were used to report toxicity. 
The initial work-up consisted of complete history and physical
examination; chest X-ray with computed tomographic (CT) scan
and fibreoptic bronchoscopy with biopsy; bone scintigrapy with 
X-rays of suspected areas; determination of ventricular ejection
fraction; liver and adrenal CT scan or echography; brain CT scan;
blood chemistries, including complete blood cell count, electrolytes,
creatinine, and liver function tests; and ECG. Blood chemistries,
ECG, chest X-ray, and clinical examination were repeated before
each course. Restaging, including all tests performed during the
initial work-up, was repeated after 3 and 6 courses of chemotherapy.
After discontinuation of therapy, patients were assessed every 2
months for 6 months and then every 3 months by clinical examina-
tion, blood chemistries, and chest X-ray. 
Patients were considered as assessable for response if they had
completed 3 courses of chemotherapy. Patients’ records were eval-
uated during regular meetings of the group by at least 3 indepen-
dent observers. Complete response (CR) was defined as the
disappearance of all signs of disease, including bronchoscopic,
for at least 4 weeks. When some doubtful small lesions remained,
the response was called minimal residual disease. In measurable
disease, partial response (PR) consisted of a ≥ 50% decrease of the
sum of the products of the 2 greatest diameters of all measurable
lesions as established by 2 observations no less than 4 weeks apart
without the appearance of new lesions or progression of any lesion.
Patients with unidimensionally measurable lesions were considered
to have assessable disease. In assessable disease, PR was defined as
an estimated decrease in tumour size of at least 50%. Progression
was defined as an increase of greater than 25% of one or more
measurable or assessable lesions or the appearance of new lesions.
All other circumstances were classified as no change. Patients with
early death due to disease progression before evaluation and those
with toxic death due to chemotherapy or early treatment discontin-
uation due to severe toxicity were considered assessable. 
The duration of response was the period between the date of
randomisation and the date of first observation of progression or
relapsing disease. Survival was measured from randomisation.
Survival curves were estimated by the Kaplan–Meier method. The
log-rank test was used to compare survival curves, and P values
(2-tailed) for testing the null hypothesis for the equality of propor-
tions were calculated using Fisher’s exact tests or χ 2 tests. A multi-
variate analysis for control of prognostic factors was performed by
adjusting the data with Cox models for duration of survival and
logistic regression models for objective response. P less than 0.05
was considered significant. 
The evaluation of chemotherapy intensity was performed by
the calculation of 3 dose-related variables. (1) The relative 1446 JP Sculier et al 
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dose-intensity (RDI) was defined, for each drug, by the ratio of the
received dose divided by the scheduled dose to the actual duration
of treatment divided by the scheduled duration. The RDI was
expressed in percentage of the projected intensity. (2) The absolute
dose-intensity (ADI) was defined as the ratio of the received dose
to the actual duration of treatment: it was calculated for each drug
and was expressed in milligrams per square metre and time unit.
(3) The absolute cumulative dose (CD) did not take time into
consideration: it was simply the sum of all received doses. CD was
calculated for each drug and was expressed in mg m–2. All the
formulas were previously reported (Sculier et al, 1993). 
Randomisation was stratified by centre, Karnofsky PS (≤ 70 vs
≥ 80), and presence of brain metastases. The procedure was
centralised and computerised. Randomisation algorithm used the
minimisation technique (Freedman and White, 1976). Treatment
assignment was obtained by calling the study data manager. The
ELCWP central office for the study coordination and analysis
(including the study coordinator, the biostatistician and the data
manager) was located at the Jules Bordet Institute in Brussels. 
The primary endpoint of the trial was survival. The study was
designed to detect a 75% relative increase of median survival time,
assumed to be 30 weeks in the control arm (arm A), in one of the
experimental arms (α = 0.05, β = 0.20) and required 78 eligible
patients in each arm and 195 deaths for statistical analysis
(Freedman, 1982). Secondary endpoints were response, toxicity
and dose-intensity. An interim analysis for toxicity was performed
after registration of the first 30 patients. No interim analysis for
survival or response was done. 
RESULTS 
243 patients were registered and randomised between April 1993
and April 2000. 10 patients were ineligible (3 in arm A, 3 in arm B
and 4 in arm C) for the following reasons: increased serum
bilirubin (1), inadequate heart function (2), non-small-cell lung
cancer histology (2), existence of a second tumour (2), initial
incomplete work-up (1), uncontrolled infection (1) and psycholog-
ical contra-indication (1). In the 233 eligible patients, 14 were non-
assessable for response (2 in arm A, 6 in arm B, an 6 in arm C) for
the following reasons: too long delay between 2 courses of
chemotherapy (1), early death unrelated to cancer or treatment
complications (9), protocol violation (2), death prior to starting
treatment (1), no work-up at evaluation (1). 
Characteristics of the eligible patients are listed in Table 1.
There were 78 patients in arm A (EVI standard), 78 in arm B
(accelerated EVI with GM-CSF) and 77 in arm C (accelerated EVI
with cotrimoxazole). The 3 arms were well balanced: 84% of the
patients were male, 75% had good Karnofsky PS (≥ 80%) and only
8% had locoregionally advanced disease without distant metas-
tases. 20% presented with brain metastases. The median follow-up
duration was 4.02 years (range: 0.45–7.49). By time of analysis,
69 in arm A, 74 in arm B and 74 in arm C had died. 14 patients
were still alive and one was lost to follow-up. 
There was no significant difference in the study arms according
to the number of courses administered: 82%, 81% and 79% of the
patients received 3 cycles of chemotherapy respectively in arms A,
B and C (the figures for 6 courses were 51%, 60% and 52%). GM-
CSF and cotrimoxazole could be administered according to treat-
ment schedule in respectively 68% (67% of the courses) and 83%
of the patients. The reasons for early discontinuation of GM-CSF
were intolerance with asthenia and/or weight loss and/or rash 
(n = 17), persistent leucopenia (n = 2) and intercurrent complica-
tions (n = 3). It was never administered in 3 patients. The causes
for early discontinuation of cotrimoxazole were lack of compli-
ance (2), allergy (3), digestive intolerance (4), prolonged neutro-
penia (1) and occurrence of infection (3). There were significantly
more treatment delays in the accelerated arms, particularly with
arm C: delays occurred during the 3 first courses in 37%, 58% and
87% of the patients respectively for arms A, B and C (P < 0.001).
For the 6 courses, the figures were respectively 69%, 85% and
97% (P < 0.001). The treatment duration was significantly shorter
(P < 0.001) in patients treated with GM-CSF support: the median
duration of the 3 first courses and that of the whole 6 courses were,
respectively for arms A, B and C, 65 and 136 days, 45 and 109
days and 63 and 143 days. 
The analysis of dose-intensity is summarised in Table 2. There
was a non-significant difference between the 3 study arms when
the cumulative doses of drugs administered were considered.
However, the absolute dose-intensity was significantly higher in
arm B and the relative dose-intensity was significantly lower in
arm C. 
As shown in Table 3, there was no statistically significant differ-
ence of response when assessment was performed after the first
3 cycles or if the best response rate was considered. The best rates
were obtained in the arm B for the evaluable patients: 69% at 3
courses and 71% as best response. These differences were signifi-
cant when directly compared to the control arm A which had
response rates of respectively 59% (P = 0.05) and 59% (P = 0.04).
There was no significant difference when arms A and C were
directly compared (P = 0.17 at 3 courses and for best response
rate). Overall, we observed only 12 complete responses and 23
minimal residual disease responses while PR was documented in
115 patients. 12 toxic deaths occurred, without difference between
the 3 arms. In subgroup analyses (Table 4), we found a significantly
higher OR rate in men in favour of arm B and in women in favour
of arm C. 
Table 1 Patients characteristics 
Arm 
ABC  
Characteristics EVI  EVI +  EVI + 
standard GM-CSF cotrimoxazole 
No of eligible patients 78 78 77 
Sex 
Male 70 65 61 
Female 8 13 16 
Age (years) 
Median 61 64 61 
Range 37–75 35–74 37–74 
PS 
60–70 18 19 20 
80–100 60 59 57 
Type of lesions 
Assessable 34 42 42 
Measurable 44 36 35 
Stage 
III 4 7 7 
IV 74 71 70 
Brain metastases 17 14 17 
Weight loss 
< 5% 38 41 42 
≥ 5% 29 28 30 British Journal of Cancer (2001) 85(10), 1444–1451 © 2001 Cancer Research Campaign
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Table 2 Dose-intensity analysis 
Arm 
AB C P
(Median) EVI EVI + GM-CSF  EVI + 
cotrimoxazole 
Cumulative doses (mg m–2) Courses 1–3 
Ifosfamide 14 700 14 700 14 600 0.48 
Vindesine 8.8 8.8 8.8 0.39 
Epirubicin 264 264 263 0.66 
Courses 1–6 
Ifosfamide 28 900 29 400 29 200 0.14 
Vindesine 17.4 17.5 17.5 0.28 
Epirubicin 524 525 525 0.49 
Absolute dose-intensity (mg/m-2 week–1) Courses 1–3 
Ifosfamide 1560 2250 1640 < 0.001 
Vindesine 0.93 1.31 0.98 < 0.001 
Epirubicin 28 40 29 < 0.001 
Courses 1–6 
Ifosfamide 1460 1840 1530 < 0.001 
Vindesine 0.87 1.09 0.93 < 0.001 
Epirubicin 26.1 33.6 27.5 < 0.001 
Relative dose-intensity (%) Courses 1–3 
Ifosfamide 93 90 65 < 0.001 
Vindesine 93 87 66 < 0.001 
Epirubicin 93 90 65 < 0.001 
Courses 1–6 
Ifosfamide 87 73 61 < 0.001 
Vindesine 87 73 62 < 0.001 
Epirubicin 87 75 61 < 0.001 
Table 4 Subgroup analyses (intent to treat analysis) 
Arm Number of patients Best OR rate (%)  Median survival (days)
AB C A BC P ABC P
Men 70 65 61 59 77 61 0.05 265 271 248 0.72 
Women 8 13 16 50 39 81 0.05 331 204 293 0.40 
PS ≤ 70 19 18 18 47 61 44 0.56 185 212 205 0.83 
PS ≥ 80 59 60 59 61 73 71 0.30 304 279 286 0.84 
Assessable lesions 34 42 42 59 64 67 0.77 265 242 271 0.80 
Measurable lesions 44 36 35 57 78 63 0.14 304 271 219 0.99 
Weight loss < 5% 38 41 42 66  71 64 0.81 320 291 236 0.32 
Weight loss ≥ 5% 29 28 30 45 71 67 0.09 230 236 248 0.77 
Age < 60 years 34 30 41 56 77 71 0.18 353 279 286 0.29 
Age ≥ 60 years 44 48 36 59  67 58 0.67 230 236 209 0.58 
Table 3 Evaluation of response 
Arm At 3 courses Best response 
A B CAB C  
Assessable patients 76 72 71 76 72 71 
CR 2 2 2 4 4 4 
Minimal residual disease 1 1 1 6  9 8 
PR 42 51 47 35 42 38 
No change 5 5 2 5 4 2 
Progression 16 1 8 16 1 8 
Early death by cancer 1 3 2 1 3  2 
Toxic death 5 4 3 5 4 3 
Stop for high toxicity 4 5 6 4 5 6 
OR rate 59% 75% 70% 59% 76%  70% 
P = 0.11 P = 0.07 
ITT OR rate 58% 69% 65% 58% 71%  65% 
P = 0.32 P = 0.25 
CR = complete response; PR = partial response; ITT = intent to treat. 1448 JP Sculier et al 
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In the analysis of prognostic factors with respect to response
(Table 5), only the Karnofsky performance status was found to be
a statistically significant prognostic factor in univariate analysis;
treatment arm, sex, weight loss, type of lesions, age and initial
neutrophil count were not found to have predictive value. 
Duration of response was not statistically different between the
arms: the estimated median times (95% confidence interval or CI)
were respectively for arm A, B and C, 241 (195–287), 186
(164–206) and 206 (176–236) days (P = 0.13). 
As shown in Figure 1, there was also no difference in survival
between the 3 arms (P = 0.86). Overall, the median survival time
(95% CI) was 286 (233–349) days for arm A, 264 (220–308) days
for arm B and 264 (223–305) days for arm C. 2-year survival rates
(95% CI) were respectively 5% (0–11%), 6% (0–12%) and 6%
(0–12%). In none of the subgroups analysed (Table 4) there was a
significant difference in survival between the 3 arms. 
Results of univariate prognostic factors analysis are listed in
Table 5. Karnofsky PS, age and initial neutrophil count were
associated with a statistically significant prognostic value.
Multivariate analysis identified as independent prognostic factors
age (HR = 1.38, 95% CI 1.03–185; P = 0.03), Karnofsky PS (HR =
0.62, 95% CI 0.44–0.88; P = 0.007) and neutrophil count (HR =
1.54, 95%
CI 1.12–2.10; P = 0.007). 
Toxicity is summarised in Table 6. The number of patients
assessable respectively for haematological and non-haematological
toxicities were respectively 74 and 77 in arm A, 74 and 77 in arm B
76 and 72 in arm C. Reasons for non-evaluability were missing
evaluations. There was no significant difference between the 3 arms
for non-haematological toxicities, including infections and bleed-
ings. Grade III–IV thrombopenia occurred significantly more
frequently in accelerated arm B. The difference was not significant
for leucopenia nadir but the duration of neutropenia was signifi-
cantly shorter in arm B during the first course of chemotherapy
(median duration of neutropenia: respectively 7, 4 and 7 days for
arms A, B and C; P = < 0.001). The number of clinical infections
observed in the different study arms is listed by grade in Table 7;
Table 5 Univariate prognostic factor analysis 
Factors Best OR rate (%) P Median survival (day) P
Treatment 
Arm A (standard) 58 286 
Arm B (GM-CSF) 71 264 
Arm C (cotrimoxazole) 65 0.25 264  0.86 
Sex 
Male 65 336 
Female 60 0.58 265 0.11 
PS 
≤ 70 51 205 
≥ 80 69 0.02 286 < 0.001 
Weight loss 
<5 % 6 7 2 8 6  
≥ 5% 61 0.38 242 0.31 
Type of lesions 
Assessable 64 269 
Measurable 65 0.89 267 0.90 
Age 
< 60 years 68 290 
≥ 60 years 62 0.41 230  0.007 
Neutrophils 
≤ 7500/mm3 66 286 
> 7500/mm3 61 0.55 209 0.003 
OR = objective response. 
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Figure 1 Survival curves of patients according to regimen (P = 0.86) 
Table 6 Toxicity evaluation (% of patients with at least one grade III or IV
during therapy, the most severe episode considered by cycle) 
Arm 
Toxicity A B C P
Leucopenia 85 84 93 0.16 
Thrombopenia 16 45 22 < 0.001 
Nausea and vomiting 9 10 14 0.63 
Diarrhoea 3 4 1 0.64 
Stomatitis 4 – 3 0.24 
Infections 18 22 14 0.43 
Bleeding 1 – 1 0.59 
Neurological 5 9 7 0.64 
Respiratory 4 4 1 0.59 
Cardiac 8 4 4 0.49 
Alopecia 30 42 42 0.23 
Renal 1 –– 0.38 British Journal of Cancer (2001) 85(10), 1444–1451 © 2001 Cancer Research Campaign
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the rate of infection increased by 41% in the accelerated arm with
GM-CSF, in comparison to the control arm but with fewer grade IV
episodes. In the cotrimoxazole arm, the global rate of infections
was similar to that of the control arm but with less grade III and IV.
12 toxic deaths were observed: 5 in arm A (3 by complicated febrile
neutropenia, 1 by septic shock and 1 by carbonarcosis), 4 in arm B
(2 by complicated febrile neutropenia, 1 by septic shock and 1 by
haemodynamic pulmonary oedema) and 3 in arm C (2 by compli-
cated febrile neutropenia and 1 by septic shock). Chemotherapy
was discontinued for treatment-related reasons in 9 patients: 4 in
arm A (cardiac failure, ifosfamide encephalopathy, tumour lysis
syndrome and infection) and 5 in arm B (2 by ifosfamide
encephalopathy, 2 by infections and 1 by allergic reaction due to
GM-CSF). 
At relapse, 100 patients received a second-line chemotherapy:
36 in arm A, 33 in arm B and 31 in arm C. The majority of the
patients received a combination of a platinum derivative (mainly
cisplatin) and etoposide: 31 in arm A, 25 in arm B and 26 in arm C.
Only 3 patients (2 in arm A and 1 in arm B) were treated by further
cycles of EVI. 
DISCUSSION 
Our study showed that the administration of the EVI
chemotherapy regimen could be accelerated with GM-CSF
support with a significant increase in the relative dose-intensity
and with a better response rate. Despite these advantages, the
survival was not improved. The same regimen could not be accel-
erated with oral antibiotics (cotrimoxazole) support. 
In the literature, there are only 2 other published trials with a
similar design (Steward et al, 1998; Thatcher et al, 2000). In
Steward’s study (Steward et al, 1998), the V-ICE (vincristine, ifos-
famide, carboplatin and etoposide) regimen was randomised to be
given over 3 or 4 weeks with or without GM-CSF support. The 3-
weekly design was associated with a significantly better survival
but the administration of GM-CSF did not result in improved
survival, despite higher delivered dose-intensity. Actually, the
latter regimen could be safely administered on a 3 weekly basis,
without GM-CSF support, and thus it does not represent truly an
accelerated chemotherapy. In Thatcher’s study (Thatcher et al,
2000), the ACE (adriamycine, etoposide, cyclophosphamide)
regimen was administered over a 2-week schedule (with G-CSF
support) versus a 3-week one (without growth factor). The experi-
mental arm resulted in significantly increased delivered dose-
intensity, complete response rate and survival. Our trial had a
design similar to that latter study, with administration of similar
individual daily dose size and total dose but we did not achieve a
better survival. Our patient population had only extensive disease
while in the other studies, there was a majority of patients with
limited disease and the number of patients with extensive disease
was smaller. 
Potential explanations can be offered to understand this differ-
ence. Firstly, the patients selection criteria were different. In our
trial, we have only included patients with extensive disease. 92%
presented with metastatic disease. In the International (Steward
et al, 1998) and British (Thatcher et al, 2000) trials, the patients
had many good prognostic characteristics and the majority had
limited disease. No subgroup analysis has been reported in these 2
papers regarding the patients with extensive disease but the
survival distributions as shown on the graphical representations
were similar to those of our patients. It is thus possible that the
beneficial effect was mainly present in limited disease and that
accelerated chemotherapy, allowing better dose-intensity, is effec-
tive in that subpopulation of patients with SCLC. This explanation
is in accordance with data of studies having shown improved
survival with increased absolute dose intensity in limited disease
(Arriagada et al, 1993) but not in extensive stage (Pujol et al,
1997). 
Our chemotherapy regimen was an association of ifosfamide,
epirubicin and vindesine. It was effective to allow acceleration
with GM-CSF support but did not contain etoposide and cisplatin,
probably the most effective drugs in SCLC as suggested by a
meta-analysis that we have recently published (Mascaux et al,
2000). The V-ICE regimen includes etoposide and carboplatin and
the ACE contains etoposide. The lack of major differences
between the 3 studies in patients with extensive disease makes it
unlikely that the drugs chosen might explain the absence of
survival improvement. Nevertheless, it should be emphasised that
platinum derivatives and etoposide were largely used for salvage
chemotherapy in our studies. About one third of the patients were
treated at progression with such combinations. Only 17% of the
patients received second-line chemotherapy in Thatcher’s trial
(Thatcher et al, 2000) and no information is given in Steward’s
paper (Steward et al, 1998) about salvage treatment. It is not
impossible that the provided salvage treatment in our study could
have improved the survival in the 3 arms. 
We have observed an increased response rate with accelerated
chemotherapy. When compared to the control arm in assessable
patients, the difference was statistically significant. This effect was
however not associated with a survival improvement. The
response rate that we have obtained was similar to those reported
in our prior trials for extensive disease (Paesmans et al, 2000); we
had relatively few complete responses: 5.5% CR (meaning
complete normalisation of all tests of the work-up) and 10.5%
minimal residual disease (meaning the persistence of some charac-
teristics that might be sequellae). This 16% rate is also similar to
the rates observed in our prior trials (Paesmans et al, 2000). It is
smaller than the rates reported by Steward and Thatcher. The
difference between the 3 studies might be explained by the pres-
ence of patients with limited disease in the latter trials and by the
severity of our criteria to define CR, requiring a full complete
work-up including bronchoscopy and CT scan. Indeed, the simi-
larity of survival in extensive disease between the 3 trials suggests
that it is more a semantic problem of definition than a true differ-
ence. In the subgroup analysis, there was a significant increased
response rate for women treated in arm C with cotrimoxazole. We
believe that this observation was mainly due to chance (multiple
tests were done) and has to be considered very cautiously, the
number of female patients being very small. 
Table 7 Number and grade of infections observed in the different study
arms 
Arm 
AB C  
Number of cycles 340 360 334 
Infections 
Grade I 10 25 14 
Grade II 15 13 17 
Grade III 13 21 7 
Grade IV 5 5 3 
Total 43 64 41 1450 JP Sculier et al 
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We have used GM-CSF as Steward did (Steward et al, 1998);
Thatcher (Thatcher et al, 2000) performed his trial with G-CSF. It
might be speculated that the choice of GM-CSF rather than G-CSF
had contributed to the lack of survival difference for several
reasons. It is less well tolerated, leading to early discontinuation as
already reported (Hamm et al, 1994). However, 67% of the courses
in our GM-CSF arm were performed with the growth factor
without problems, allowing a very significant chemotherapy accel-
eration. In the Steward’s trial, where patients were randomised
between GM-CSF and placebo in a double-blind design, no signif-
icant difference was observed in term of toxicity and treatment
discontinuation. An adverse effect of GM-CSF is thus unlikely. In
another study (Bunn et al, 1995), where GM-CSF was given
concomitantly to chest irradiation, more toxicity in terms of infec-
tion and thrombopenia was observed and there was a trend for
decreased survival with GM-CSF. An effect of radiotherapy on
circulating blood stem cells stimulated by GM-CSF has been
advanced to explain the observation. In our trial, radiotherapy was
not used; nevertheless, we observed more toxicity in the acceler-
ated arm with GM-CSF. There was a significantly increased
haematological toxicity, consisting mainly of more severe throm-
bopenia, but with fewer bleeding complications. This is a logical
consequence of acceleration since the growth factor has no effect
on the platelet recovery. A similar toxicity has been observed in all
the trials having studied chemotherapy acceleration (Steward et al,
1998; Thatcher et al, 2000). 
More infections have also been documented in the GM-CSF
arm. In comparison to the control arm, the rate of infection
increased by 41%. The difference was restricted to the fewer
severe infections and there were no more toxic deaths. This effect
is probably due to more overall prolonged myelosuppression, the
patients receiving chemotherapy without waiting for full haemato-
logical recovery. We could not provide a detailed analysis of the
duration of neutropenia because the design of our trial did not
include repeated detailed haematological tests during each cycle. 
A systematic review of the literature has shown that there are
data supporting the administration of consolidation and mainte-
nance chemotherapy (Sculier et al, 1998). In addition, Pujol (Pujol
et al, 1997) has shown in a randomised trial that the concentration
of chemotherapy over only 4 cycles was associated with shorter
survival in comparison to standard 6 cycles treatment, despite the
administration of similar theoretical cumulative doses in the 2
arms. This result suggests also that a too-short treatment might not
be optimal for SCLC and might explain, partly at least, the lack of
effect of our accelerated regimens on survival. 
In our study design, we had an arm (arm C) attempting to
provide chemotherapy acceleration with support of cotrimoxazole.
We made the hypothesis that a prevention of the infectious
episodes might allow acceleration of chemotherapy as well as the
shortening of neutropenia duration, with GM-CSF. In fact, it was
impossible to accelerate chemotherapy without the growth factor
support. Nevertheless, we observed fewer severe infections
(Table 7) with cotrimoxazole preventive administration, confirming
data obtained in trials published in the early 1980s (de Jongh et al,
1983; Figueredo et al, 1985). 
In conclusion, the results of our randomised study do not
support the practice of chemotherapy acceleration via the
support by haematological growth factors in extensive-disease
small-cell lung cancer. Despite a better objective response rate,
survival was not improved. Our data support the 2000 recommen-
dations of the American Society of Clinical Oncology for the use
of haematopoietic CSF in cancer patients (Ozer et al, 2000).
Nevertheless, the concept of accelerated chemotherapy might be
further tested in patients with better prognosis, as those with
limited disease, in appropriately designed randomised controlled
trials. A comparison between G-CSF and GM-CSF support might
be useful in that type of patients. 
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